Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). A case report and survey.

M Gillingham, S Van Calcar, D Ney, J Wolff, C Harding
Author Information
  1. M Gillingham: Waisman Center, Department of Pediatrics, University of Wisconsin-Madison, USA.

Abstract

Current dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD; long-chain-(S)-3-hydroxyacyl-CoA:NAD+ oxido-reductase, EC 1.1.1.211) deficiency (LCHADD) is based on avoiding fasting, and minimizing energy production from long-chain fatty acids. We report the effects of various dietary manipulations on plasma and urinary laboratory values in a child with LCHADD. In our patient, a diet restricted to 9% of total energy from long-chain fatty acids and administration of 1.5 g medium-chain triglyceride oil per kg body weight normalized plasma acylcarnitine and lactate levels, but dicarboxylic acid excretion remained approximately ten times normal. Plasma docosahexaenoic acid (DHA, 22:6n-3) was consistently low over a 2-year period; DHA deficiency may be related to the development of pigmentary retinopathy seen in this patient population. We also conducted a survey of metabolic physicians who treat children with LCHADD to determine current dietary interventions employed and the effects of these interventions on symptoms of this disease. Survey results indicate that a diet low in long-chain fatty acids, supplemented with medium-chain triclyceride oil, decreased the incidence of hypoketotic hypoglycaemia, and improved hypotonia, hepatomegaly, cardiomyopathy, and lactic acidosis. However, dietary treatment did not appear to effect peripheral neuropathy, pigmentary retinopathy or myoglobinuria.

References

  1. Exp Eye Res. 1970 Oct;10(2):339-44 [PMID: 4320824]
  2. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):841-5 [PMID: 7846063]
  3. J Pediatr. 1994 Sep;125(3):509-10 [PMID: 8071774]
  4. Hepatology. 1994 Feb;19(2):339-45 [PMID: 8294091]
  5. J Nutr. 1960 Mar;70:405-10 [PMID: 14402760]
  6. Mol Cell Biochem. 1997 Mar;168(1-2):101-15 [PMID: 9062899]
  7. Biochem Mol Med. 1996 Jun;58(1):59-65 [PMID: 8809347]
  8. Am J Clin Nutr. 1987 Jan;45(1):66-77 [PMID: 2879436]
  9. J Lipid Res. 1990 Feb;31(2):237-47 [PMID: 2139096]
  10. Eur J Pediatr. 1991 Jan;150(3):190-5 [PMID: 2044590]
  11. Lipids. 1992 Nov;27(11):886-95 [PMID: 1362792]

Grants

  1. M01 RR000334/NCRR NIH HHS
  2. M01 RR000334-340613/NCRR NIH HHS

MeSH Term

3-Hydroxyacyl CoA Dehydrogenases
Adolescent
Child
Child, Preschool
Dietary Fats
Female
Health Surveys
Humans
Infant
Infant, Newborn
Lipid Metabolism, Inborn Errors
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase
Male

Chemicals

Dietary Fats
3-Hydroxyacyl CoA Dehydrogenases
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase

Word Cloud

Created with Highcharts 10.0.0long-chaindietary1LCHADDdeficiencyfattyacidsmanagement3-hydroxyacyl-CoAdehydrogenaseenergyreporteffectsplasmapatientdietmedium-chainoilacidDHAlowpigmentaryretinopathysurveyinterventionsCurrentLCHADlong-chain-S-3-hydroxyacyl-CoA:NAD+oxido-reductaseEC211basedavoidingfastingminimizingproductionvariousmanipulationsurinarylaboratoryvalueschildrestricted9%totaladministration5gtriglycerideperkgbodyweightnormalizedacylcarnitinelactatelevelsdicarboxylicexcretionremainedapproximatelytentimesnormalPlasmadocosahexaenoic22:6n-3consistently2-yearperiodmayrelateddevelopmentseenpopulationalsoconductedmetabolicphysicianstreatchildrendeterminecurrentemployedsymptomsdiseaseSurveyresultsindicatesupplementedtriclyceridedecreasedincidencehypoketotichypoglycaemiaimprovedhypotoniahepatomegalycardiomyopathylacticacidosisHowevertreatmentappeareffectperipheralneuropathymyoglobinuriaDietarycase

Similar Articles

Cited By (22)